EQUITY RESEARCH COMPANY UPDATE

Biotechnology

IMMP - NASDAQ	March 6, 2019
Intraday Price 03/6/2019	\$2.33
Rating:	Buy
12-Month Target Price:	\$7.00
52-Week Range:	\$1.70 - \$4.21
Market Cap (M):	77.8
Shares O/S (M):	33.4
Float:	NA
Avg. Daily Volume (000):	46
Debt (M):	\$6.2
Dividend:	\$0.00
Dividend Yield:	0.0%
Risk Profile:	Speculative
Fiscal Year End:	June

Total Expenses ('000)					
	2018A	2019E	2020E		
H1	7,058	8,364A	8,515		
H2	7,032	8,531	9,225		
FY	14.090	16.895	17.739		



Jason McCarthy, Ph.D. (212) 895-3556 jmccarthy@maximgrp.com

Caroline Palomeque (212) 895-3726 cpalomeque@maximgrp.com

Immutep Limited

Buy

Advancing the Second Merck Collaboration, TACTI-002 Doses First Patient


Summary

- Immutep announced the dosing of the first patient in the P2 TACTI-002 basket study of its lead asset eftilagimod alpha ('efti', LAG-3) with Merck's (MRK -NR) Keytruda, evaluating the combination in PD-X naïve or refractory patients (lung and head & neck).
- The P2 study (TACTI-002) is enrolling up to N=109 patients in 13 centers across the US, EU, and Australia.
- Recall, Keytruda is approved in both the 1L and 2L settings for lung and 2L in H&N. In our view, as Keytruda is likely becoming the standard of care in 1L lung with chemo + Keytruda combo (approval was based on overall response rate of 58% vs. 38% chemo alone), the bar is higher. However, Keytruda as monotherapy in H&N was approved in 2L with an ORR of 16%, and a complete response (CR) rate of 5%.
- Incremental but positive. More mature TACTI-mel data (N=24) was presented at the World Immunotherapy Congress 2019 in San Diego on 3/5. The results from Part A of the study (3 cohorts, n=18 total), where efti is added at cycle 5 of Keytruda, continues to show durability (up to 30 months from the previous 27 months reported; see our note from <u>11/27</u>) with ORR of 33%. In Part B (n=6), where efti is given cycle 1, day 1 of Keytruda, ORR also remains consistent at 50% with treatment ongoing 6+ months in four patients.
- Conclusion. For checkpoints, the future lays in combination treatments. Immutep's five collaborations {GlaxoSmithKline (GSK - NR), Novartis (NVS - NR), EOC Pharma (private), Merck, and Merck KGaA/Pfizer (PFE - NR)}, four in the oncology space, lends further support for its LAG-3 program.

Details

Merck collaboration (efti + Keytruda combo): Eftilagimod, TACTI-mel study. P1 (N=24) efti + Keytruda in patients with unresectable or metastatic melanoma that have poor responses or have had disease progression on Keytruda monotherapy. The study is now fully enrolled with the final patient in Part B (n=6) recruited and dosed with treatment. Positive data from Part A (n=18) has been reported with early positive data from Part B as well. Durable responses continue to be seen in Part A (up to 30 months now vs. 27 months previously reported). Overall response rates of 33% and disease control rate of 66% remained consistent with previous disclosures for Part A. No new safety signals were observed. Tumor shrinkage was observed in 10 (56%) of patients, including two that had complete disappearance of all lesions. Four patients still remain on progression free survival (PFS) follow up after 12 months. In Part B, combination treatments were initiated from the beginning of cycle 1, day 1 of Keytruda. An ORR of 50% has been demonstrated to date, with deep partial responses seen in these patients. Treatment of 4 patients is ongoing (6+ months, up from prior 3 months reported). The data thus far are suggestive that efti, as an immune activator, is enhancing the immune response to otherwise "cold tumors". Final data is expected later in 2019. Eftilagimod, TACTI-002 study. The open-label, multi-center P2 collaboration with Merck in NSCLC (1L PDX-naive and 2L PDX-refractory) and HNSCC cancer (2L PDX-naive) will enroll up to N=109, across ~13 sites in US, EU and Australia. Patient recruitment initiated 1Q19, with 7 sites open to date in US (1), EU (4) and Australia (2); initial data 2H19. The primary endpoint of the study is objective response rate (ORR) according to iRECIST. Key secondary endpoints include: safety and tolerability of the combo; response rate according to RECIST 1.1; disease control rate (DCR); progression free survival (PFS); overall survival (OS); and pharmacokinetic and immunogenicity profile of efti.

DISCLOSURES



Maxim	Group LLC Ratings Distribution		As of: 03/05/19
		% of Coverage Universe with Rating	% of Rating for which Firm Provided Banking Services in the Last 12 months
Buy	Fundamental metrics and/or identifiable catalysts exist such that we expect the stock to outperform its relevant index over the next 12 months.	84%	37%
Hold	Fundamental metrics are currently at, or approaching, industry averages. Therefore, we expect this stock to neither outperform nor underperform its relevant index over the next 12 months.	15%	22%
Sell	Fundamental metrics and/or identifiable catalysts exist such that we expect the stock to underperform its relevant index over the next 12 months.	1%	0%
	*See valuation section for company specific relevant indices		

I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Caroline Palomeque, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm's total revenues, a portion of which is generated by investment banking activities.

Maxim Group makes a market in Immutep Limited

Maxim Group expects to receive or intends to seek compensation for investment banking services from Immutep Limited in the next 3 months.

IMMP: For Immutep, we use the BTK (Biotechnology Index) as the relevant index.

Valuation Methods

IMMP: Our therapeutic model assumes a royalty structure for each LAG-3 product, initially with IMP701 and IMP731 in 2020 and followed by IMP321 in 2023 (breast cancer). Our models assume risk adjustments for each product based on the stage(s) of development. Our therapeutic

models assume a risk adjustment. We then apply a 30% discount to our free-cash-flow, discounted EPS, and sum-of-the-parts models, which are equally weighted to derive a price target.

Price Target and Investment Risks

IMMP: Aside from general market and other economic risks, risks particular to our price target and rating for Immutep include: (1) Development— To date, LAG-3 checkpoint modulators have not been approved; (2) Regulatory—The company's ongoing and future studies may not be sufficient to gain approval; (3) Commercial—The company lacks commercial infrastructure to support a launch if approved; (4) Financial—The company is not yet profitable and may need to raise additional capital to fund operations; (5) Collaborative—The company has ongoing collaborations with large pharmaceutical companies who could back out of the partnerships, setting back development on product lines and increasing costs; (6) High volatility of the company's stock price.

RISK RATINGS

Risk ratings take into account both fundamental criteria and price volatility.

Speculative – <u>Fundamental Criteria</u>: This is a risk rating assigned to early-stage companies with minimal to no revenues, lack of earnings, balance sheet concerns, and/or a short operating history. Accordingly, fundamental risk is expected to be significantly above the industry. <u>Price Volatility</u>: Because of the inherent fundamental criteria of the companies falling within this risk category, the price volatility is expected to be significant with the possibility that the investment could eventually be worthless. Speculative stocks may not be suitable for a significant class of individual investors.

High – <u>Fundamental Criteria</u>: This is a risk rating assigned to companies having below-average revenue and earnings visibility, negative cash flow, and low market cap or public float. Accordingly, fundamental risk is expected to be above the industry. <u>Price Volatility</u>: The price volatility of companies falling within this category is expected to be above the industry. High-risk stocks may not be suitable for a significant class of individual investors.

Medium – <u>Fundamental Criteria</u>: This is a risk rating assigned to companies that may have average revenue and earnings visibility, positive cash flow, and is fairly liquid. Accordingly, both price volatility and fundamental risk are expected to approximate the industry average.

Low – <u>Fundamental Criteria</u>: This is a risk rating assigned to companies that may have above-average revenue and earnings visibility, positive cash flow, and is fairly liquid. Accordingly, both price volatility and fundamental risk are expected to be below the industry.

DISCLAIMERS

Some companies that Maxim Group LLC follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Maxim Group LLC research reports may not be suitable for some investors. Investors must make their own determination as to the appropriateness of an investment in any securities referred to herein, based on their specific investment objectives, financial status and risk tolerance.

This communication is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned herein. This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of Maxim Group, LLC ("Maxim").

Information and opinions presented in this report have been obtained or derived from sources believed by Maxim to be reliable, but Maxim makes no representation as to their accuracy or completeness. The aforementioned sentence does not apply to the disclosures required by FINRA Rule 2241. Maxim accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Maxim. This report is not to be relied upon in substitution for the exercise of independent judgment. Maxim may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and Maxim is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by Maxim and are subject to change without notice. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. The value of securities is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Securities recommended, offered or sold by Maxim: (1) are not insured by the Federal Deposit Insurance Company; (2) are not deposits or other obligations of any insured depository institution; and (3) are subject to investment risks, including the possible loss of principal invested. Indeed, in the case of some investments, the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support these losses.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST



Corporate Headquarters

The Chrysler Building 405 Lexington Ave., 2nd FL New York, NY 10174 Tel: 212-895-3500

Capital Markets/Syndicate: 212-895-3695 Corporate Finance: 212-895-3811 Corporate Services: 212-895-3631 Equity/Options Trading: 212-895-3790 Equity Research: 212-895-3736 Fixed Income Trading: 212-895-3875 Global Equity Trading: 212-895-3623 Institutional Sales: 212-895-3873 Institutional Sales Trading: 212-895-3873 Port./Transition Trading: 212-895-3567 Prime Brokerage: 212-895-3723 Wealth Management: 212-895-3624

Woodbury, Long Island

20 Crossways Park Drive North Suite 304 Woodbury, NY 11797 Tel: 516-393-8300

West Palm Beach, Florida

105 South Narcissus Avenue Suite 222 West Palm Beach, FL 33401 Tel: 561-508-4433

Red Bank, New Jersey

246 Maple Avenue Red Bank, NJ 07701 Tel: 732-784-1900

San Rafael, California

4040 Civic Center Drive Suite 200 San Rafael, CA 94903 Tel: 212-895-3670